Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus
出版年份 2016 全文链接
标题
Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 15, Issue 10, Pages 1401-1412
出版商
Informa UK Limited
发表日期
2016-07-23
DOI
10.1080/14740338.2016.1216100
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
- (2016) Sven Kohler et al. CLINICAL THERAPEUTICS
- Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
- (2016) André J. Scheen DIABETES & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY
- (2016) Alan J. Garber et al. Endocrine Practice
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS
- (2016) Yehuda Handelsman et al. Endocrine Practice
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The EMPA-REG study: What has it told us? A diabetologist’s perspective
- (2016) Ralph A. DeFronzo JOURNAL OF DIABETES AND ITS COMPLICATIONS
- The effect of dapagliflozin on renal function in patients with type 2 diabetes
- (2016) Donald Elliott Kohan et al. JOURNAL OF NEPHROLOGY
- Type 2 diabetes and the skeleton: new insights into sweet bones
- (2016) Vikram V Shanbhogue et al. Lancet Diabetes & Endocrinology
- Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment
- (2015) Heidi Storgaard et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2015) André J. Scheen CLINICAL PHARMACOKINETICS
- The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
- (2015) Karen Whalen et al. CLINICAL THERAPEUTICS
- Renal effects of canagliflozin in type 2 diabetes mellitus
- (2015) Vlado Perkovic et al. CURRENT MEDICAL RESEARCH AND OPINION
- Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
- (2015) A.J. Scheen et al. DIABETES & METABOLISM
- Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes After Treatment With Empagliflozin
- (2015) Paris Roach et al. DIABETES CARE
- 7. Approaches to Glycemic Treatment
- (2015) DIABETES CARE
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
- (2015) Ngozi Erondu et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
- (2015) T. R. Pieber et al. DIABETES OBESITY & METABOLISM
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Latent autoimmune diabetes of the adult: current knowledge and uncertainty
- (2015) E. Laugesen et al. DIABETIC MEDICINE
- SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
- (2015) André J. Scheen Expert Opinion On Drug Safety
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials
- (2015) Rizwana Parveen et al. EXPERT OPINION ON PHARMACOTHERAPY
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes
- (2015) Hadi Harati et al. Journal of Diabetes
- SGLT inhibition and euglycaemic diabetic ketoacidosis
- (2015) Julia Hine et al. Lancet Diabetes & Endocrinology
- Understanding EMPA-REG OUTCOME
- (2015) Antonio Ceriello et al. Lancet Diabetes & Endocrinology
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
- (2014) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Ketosis-Prone Type 2 Diabetes in a Veteran Population
- (2014) Gelsey Goodstein et al. DIABETES CARE
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
- (2014) Suzanne Geerlings et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
- (2014) Agata Ptaszynska et al. DRUG SAFETY
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
- (2014) Xu-Ping Yang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport
- (2014) M. A. Abdul-Ghani et al. JOURNAL OF INTERNAL MEDICINE
- Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
- (2014) B Haas et al. Nutrition & Diabetes
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus
- (2014) Aris Liakos et al. Therapeutic Advances in Endocrinology and Metabolism
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
- (2013) Bruce Neal et al. AMERICAN HEART JOURNAL
- Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
- (2013) M. A. Abdul-Ghani et al. DIABETES
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2013) Mei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
- (2013) Muhammad Abdul-Ghani et al. Endocrine Practice
- Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Effects of Dapagliflozin on Cardiovascular Risk Factors
- (2013) Agata Ptaszynska et al. POSTGRADUATE MEDICINE
- FGF23 associated bone diseases
- (2013) Eryuan Liao Frontiers of Medicine
- Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
- (2013) Harold Bays Diabetes Therapy
- Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor
- (2012) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Minireview: Glucagon in Stress and Energy Homeostasis
- (2012) B. J. Jones et al. ENDOCRINOLOGY
- Diagnostic Accuracy of Point-of-Care Testing for Diabetic Ketoacidosis at Emergency-Department Triage: -Hydroxybutyrate versus the urine dipstick
- (2011) S. Arora et al. DIABETES CARE
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
- (2011) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Hyperglycemic Crises in Adult Patients With Diabetes
- (2009) A. E. Kitabchi et al. DIABETES CARE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started